Table of Contents
What changed
Revenue rose 14.2% to $10.2m and the net loss narrowed by $1.4m to $1.4m (PBT identical, with nil tax in both periods so PBT growth of 50.1% is a clean operating read). Operating cash flow swung to a $0.1m inflow from a $2.3m outflow. Gross borrowings were eliminated, but cash and equivalents fell 49.9% to $4.3m, total equity declined 10.8% to $10.8m, and total assets fell 9.4% to $12.8m. No FY23 EBITDA figure was disclosed (FY22: -$2.1m). No dividend was declared, consistent with the prior period.
What matters
- Second-half swing to profit. H1 carried a $1.7m loss on $4.3m revenue; the implied H2 delivered ~$5.9m revenue and a ~$0.3m NPAT profit. That is the first tangible evidence the July 2022 B2B pivot is converting to earnings, not just revenue.
- Cash base shrank despite positive OCF. Operating cash flow was only +$0.1m, yet cash fell $4.2m. The gap is not explained in the supplied excerpts (capex and investing/financing lines are not disclosed), but it means the balance-sheet runway is materially thinner entering FY24.
- Working-capital release flattered operating cash. Receivable days improved from 68.7 to 51.7 and inventory days from 31.8 to 26.2, releasing roughly $0.3m of operating working capital — a meaningful share of the $2.4m OCF improvement.
Expectations
No quantitative targets, guidance, or forward-work metrics were disclosed. Against the shape of the year, H2 is clearly stronger than H1 on both revenue (58.1% of full year) and profitability (H2 profit offsetting the H1 loss), so a simple H2-annualised run-rate implies ~$11.9m revenue capacity if that cadence holds. The release does not support or rule out that extrapolation; it only shows the trajectory turned positive within the year.
Quality of result
Mixed. The PBT improvement is genuine and is not a tax artefact — the effective tax rate was zero in both periods. However, the $2.4m OCF swing was assisted by working-capital release (lower receivables and inventory) rather than being purely earnings-driven, and with EBITDA not disclosed for FY23 the underlying cash conversion cannot be directly benchmarked. The 50% cash decline against a $0.1m OCF print is the clearest quality flag: something below the operating line (capex, investing, or lease outflows that are not broken out in the supplied data) consumed roughly $4.3m of cash. The H2 profitability is durable-looking on its face, but rests on a single half of evidence.
Unresolved
- What consumed the $4.2m of cash between operating cash flow and the closing balance? Capex, investment, and lease payment lines are not in the supplied excerpts.
- Is the H2 profit repeatable, or did it benefit from one-off phasing (e.g. shipment timing with Probi or European partners referenced in HY23 commentary)?
- What is the FY23 EBITDA and gross margin? Neither was disclosed in the supplied data, making it impossible to separate volume, mix, and cost leverage.
- With cash at $4.3m and no borrowings, how many quarters of runway does management see if FY24 reverts toward an H1-style loss?
This briefing cannot assess capital-expenditure intensity, segment or customer mix, or whether the H2 profit print is a trend or a single-period outcome, because those disclosures are not present in the supplied extraction.
Key metrics
| Metric | FY23 | FY22 | Change |
|---|---|---|---|
| Revenue | $10.2m | $9.0m | +14.2% ↑ |
| EBITDA | — | −$2.1m | — |
| Net profit after tax | −$1.4m | −$2.7m | +50.1% ↑ |
| Net cash inflow from operating activities | $0.1m | −$2.3m | +104.6% ↑ |
| Final dividend per share | 0.0c | 0.0c | flat |
| Profit before tax | −$1.4m | −$2.7m | +50.1% ↑ |
| Cash and cash equivalents | $4.3m | $8.5m | -49.9% ↓ |
| Total assets | $12.8m | $14.1m | -9.4% ↓ |
Reference: annolyse.ai/briefings/blt-fy23
Analytical metrics
| Metric | FY23 | FY22 | Context |
|---|---|---|---|
| Debtor days | 51.7 | 68.7 | -17.0 days |
| Inventory days | 26.2 | 31.8 | -5.7 days |
| Operating working capital | $2.2m | $2.5m | −$0.3m absorbed |
| Trade debtors | $1.4m | $1.7m | −$0.2m |
| Net debt | −$4.3m | −$8.5m | +$4.2m |
| Gross borrowings | $0.0m | $0.0m | −$0.0m |
| Payout ratio vs NPAT | 0.0% | — | — |
| ROE (annualised) | -12.5% | -22.3% | Strengthening |
| HY23 share of FY23 revenue | 41.9% | — | Other half was 58.1% |
| HY23 share of FY23 NPAT | 125.1% | — | Other half was -25.1% |
| Profit from continuing operations | −$1.4m | −$2.7m | +$1.4m |
Reference: annolyse.ai/briefings/blt-fy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.